Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Serdexmethylphenidate/dexmethylphenidate - Zevra Therapeutics

Drug Profile

Serdexmethylphenidate/dexmethylphenidate - Zevra Therapeutics

Alternative Names: AK-0901; AZSTARYS; D-methylphenidate prodrug - Zevra Therapeutics; D-threo-methylphenidate prodrug - Zevra Therapeutics; KP 415; Methylphenidate-prodrug- Zevra Therapeutics; SDX - Zevra Therapeutics; SDX/d-MPH - Zevra Therapeutics; Serdexmethylphenidate chloride - Zevra Therapeutics; Serdexmethylphenidate/d-MPH - Zevra Therapeutics

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KemPharm
  • Developer Ark Biosciences; Zevra Therapeutics
  • Class Amines; Behavioural disorder therapies; Drug withdrawal therapies; Ethers; Phenylacetates; Piperidines; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Central nervous system stimulants; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 26 Jun 2023 The US label for serdexmethylphenidate/dexmethylphenidate carries a blackbox warning for the high potential for abuse and dependence associated with CNS stimulants, including AZSTARYS, other methylphenidate-containing products, and amphetamines. Additional warning about serious cardiovascular disorders, psychotic or manic symptoms, prolonged penile erections and priapism, Raynaud's phenomenon, and growth suppression in pediatric patients
  • 22 May 2023 Updated adverse events data from a phase III trial in Attention-deficit hyperactivity disorder (In children) released by Corium
  • 22 Feb 2023 Efficacy and adverse events data from a phase III trial in Attention-deficit hyperactivity disorder released by Corium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top